Sorry, this entry is only available in Ukrainian.
Вас может заинтересовать:
WEB only
Investment of 350 million EUR in state-of-the-art research infrastructure is Boehringer Ingelheim’s largest single investment in Germany to date Boehringer Ingelheim strengthens innovation power and development of biopharmaceuticals, which account…
WEB only
Farmak increases its presence in the EU countries by acquiring pharmaceutical marketing companies in the Czech Republic and Slovakia, together with the relevant IP rights and trademarks. The seller in…